Study of VERVE-102 for high cholesterol or early heart disease
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a new medicine called VERVE-102 for people with a specific type of high cholesterol (HeFH) or early coronary artery disease. It aims to see if it can help lower cholesterol levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a genetic condition causing high cholesterol (HeFH) or early heart disease.
- You do NOT have a more severe form of genetic high cholesterol (HoFH).
- You do NOT have active or past chronic liver disease.
- You are not currently taking or recently stopped a PCSK9 inhibitor (a type of cholesterol-lowering injection).
- Your routine lab results are within acceptable ranges as defined by the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who already received an experimental gene editing treatment for cardiovascular disease in a prior Verve trial. The goal is to monitor their health and any long-term effects over time.
This trial tests a new injection called ART002g1 for people with a genetic condition that causes very high cholesterol. It aims to see if the drug is safe and can help lower cholesterol levels.
This study tests a new injectable medication called HST101 for lowering cholesterol in people who are already taking cholesterol pills but still have high levels. It may help if you have heart disease or are at high risk.
This trial tests a new one-time treatment called VERVE-201 for people with very high cholesterol or triglycerides that don't get better with standard medicines. The goal is to see if it can safely lower these fats in your blood.
This trial tests an experimental medication called QLC7401 for people with a genetic condition that causes very high cholesterol. It aims to lower cholesterol levels safely and may be an option for those who need better control.
This trial tests a new gene therapy called YOLT-101 for people with familial hypercholesterolemia, a genetic condition that causes very high cholesterol. The treatment aims to lower cholesterol levels and reduce heart risks.
Hear when a new Heterozygous Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.